Radiopharm Theranostics Receives AU$5.9 Million R&D Tax Refund for Fiscal Year 2025
Radiopharm Theranostics (ASX:RAD) received its research and development (R&D) tax refund for the fiscal year 2025, totalling AU$5.9 million, including AU$104,475 in interest, according to a Friday Australian bourse filing. The refund will provide funding for continued development of its portfolio of radiopharmaceutical products for diagnostic and therapeutic applications, it added.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.